articles

As September and Blood Cancer Awareness Month wrap up, we want to reflect on a memorable conversation with Karen Thomas, a woman who received clonoSEQ® testing, and her physician, Dr. Hazma Hashmi, a hematologist-oncologist from the Medical University of South Carolina. At Adaptive, we know our diagnostic tests provide key information that help physicians and patients make treatment de

The day a person receives a cancer diagnosis is likely one of the worst days of their lives. For some new patients, the typical approach may be to seek care from a specialist at an NCCN-designated cancer center. But for the majority of Americans, it will be a community oncologist who guides them through their cancer journey.

That’s why Adaptive recently partnered as a sponsor

This September marks four years since the 2018 Food and Drug Administration clearance for clonoSEQ to detect and monitor minimal residual disease (MRD) in bone marrow from patients with acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). In the years following, researchers have explored the value of using MRD status to guide treatment in blood cancers – and the mounting evi

Here at Adaptive we understand that fostering an empowering environment for future STEM leaders through rich mentoring opportunities will be key to enabling them to find their own professional paths later in life.

In March, Adaptive hosted a Field Day for you

Here at Adaptive, putting the patient first is a core value—a philosophy that deeply resonates with me. Similar to many of my fellow Adapters, my inspiration is personal and I’m excited by the tremendous potential impact we can have on human lives through the work we’re doing in our Immune Medicine and MRD businesses.

Growing up in New Delhi, India, my father work